Skip to content

Patient experience and advocacy

TL;DR — GAD's qualitative literature is small but not singular. A live PubMed search rerun on 2026-09-02 located direct work on values and treatment decisions (Hurtado 2020, PMID 31908140), primary-care implementation (Toledo-Chávarri 2020, PMID 33218311), perinatal behaviours (Inness 2022, PMID 35716017), motivational-interviewing experience (Marcus 2011, PMID 21644188), and participant experience in a dietary trial (Aucoin 2026, PMID 41587136). Hurtado participants reported physical symptoms, little social support, occupational interference, and scarce involvement in decisions, with medication always offered first. A commissioned UK randomised trial of medication versus psychological therapy was terminated for recruitment failure: three-quarters of eligible patients declined, mostly to avoid possible randomisation to medication (Kalpakidou 2019, PMID 31126337, ISRCTN14845583). A later quasi-experimental study successfully let participants choose e-CBT, medication or both, but preference confounding prevents a causal comparison (Stephenson 2023, PMID 38125282). Globally, WHO reports 359 million people with anxiety disorders in 2021 and about 27.6% of those needing treatment receiving any (WHO fact sheet, accessed 2026-09-02). The full patient-voice layer is at literature/patient-voice/.

What people with GAD report

Seven themes, each supported by ≥2 independent sources and reported in aggregate (themes.md):

# Theme Core evidence
T1 Anxiety presents as a physical illness. Most GAD participants reported physical symptoms as the presenting experience; primary-care patients described being puzzled by symptoms and not recognising them as emotional Hurtado 2020, PMID 31908140; Parker 2020, PMID 32059636; quantitatively, painful physical symptoms in 59.0% vs 28.3% of controls (Romera 2010, PMID 20541811)
T2 Choice is rarely offered; medication is the default. Patient involvement "scarce"; medication always first Hurtado 2020, PMID 31908140; and the trial that could not recruit because patients refused randomisation to medication (Kalpakidou 2019, PMID 31126337)
T3 Self-reliance and stigma delay help-seeking, in gendered ways. Men favour self-reliance and problem-based coping; help-seeking itself transgresses masculinity norms Fisher 2021, PMID 34517242 (25 studies); Lui 2024, PMID 36084266 (barriers: self-reliance, stigma, mental-health literacy)
T4 Isolation and work interference are core, not secondary. Little perceived social support; in youth, a "fractured sense of self" with responsibility for others at the cost of self Hurtado 2020, PMID 31908140; Woodgate 2020, PMID 32004336 (n=58, ages 10–22)
T5 Stopping medication is a distinct, under-supported experience — emotional blunting released, relationships affected, tapering needs to be gradual and flexible Mahmood 2024, PMID 39102706; Boland 2025, PMID 40790920 (483 free-text responses, James Lind Alliance priority-setting)
T6 Perinatal anxiety is described as invisible beside perinatal depression Oh 2020, PMID 33380483; Ali 2018, PMID 29881312; Saeed 2024, PMID 38772885
T7 Patients want continuity and validation — "doctor as drug, detective and collaborator" Parker 2020, PMID 32059636; Hurtado 2020, PMID 31908140

Treatment preference is a measurable force, not a courtesy

The Kalpakidou analysis is the strongest datum in this page because it quantifies preference by watching it destroy a trial (Kalpakidou 2019, PMID 31126337):

Finding Value
Potentially suitable patients who declined Three-quarters
Dominant reason Did not want to be randomly assigned to receive medication
Potentially eligible patients actually identified by recruiting practitioners ~12%
Of those with GAD-7 ≥10 at service entry, proportion who would have been eligible 5%
Outcome Trial discontinued prematurely by its NIHR funders for recruitment failure

Two implications. First, the comparative-effectiveness question that guidelines most need answered — drug versus therapy, head to head, in GAD — may be structurally unanswerable by randomisation in a population with strong preferences (cognitive behavioural therapy, guidelines). Second, the 5% eligibility figure shows how far a trial population sits from the screened service population, which is the generalisability problem in one number (screening and measurement).

Guidelines already say preference should decide (Bandelow 2014, PMID 25138725). The patient-reported evidence says it does not (Hurtado 2020, PMID 31908140). That gap is the most actionable finding on this page.

Does treatment feel helpful? The patient-rated answer

Treatment guidelines rest on trials; almost none of them asks patients whether the treatment they received felt helpful. The WHO World Mental Health surveys did, across 23 countries, with DSM-5 GAD assessed by CIDI 3.0 (Stein 2021, PMID 34372811):

Question Answer
GAD prevalence in these surveys 4.5% (2.8% low/middle-income, 5.3% high-income countries)
Ever obtained treatment for GAD 34.6% (19.2% LMIC, 38.4% HIC)
Of those treated, ever considered it helpful 70% — comparable in low/middle- and high-income countries
Modelled: would obtain helpful treatment if they persisted with up to 10 professionals Virtually all
Estimated proportion who would persist that long 29.7%
What predicted obtaining helpful treatment Treatment type, comorbid panic/agoraphobia and childhood adversities — but mostly because they predicted persistence, not encounter-level helpfulness

This is the most patient-centred finding in the condition and it reframes the treatment gap. It is not principally that treatments do not work, nor that patients do not value them — 70% of treated patients found their treatment helpful. It is that most people stop looking after an unhelpful encounter, and the modelled ceiling on helpfulness is reached only by persisting through several. Everything in themes T2 (choice rarely offered), T3 (self-reliance and stigma) and T7 (continuity and validation) describes the mechanisms by which persistence fails.

Who seeks treatment at all is also patterned: in NESARC-III, comorbid depression, panic disorder and PTSD each independently raised the odds of GAD-related treatment seeking, along with fatigue, panic attacks, reassurance-seeking and interpersonal avoidance (Zech 2024, PMID 39047416). The person with pure GAD — impaired as much as a person with pure major depression (Hoffman 2008, PMID 17146763) — is among the least likely to present.

Advocacy landscape

Full verified directory with HTTP statuses and access dates: organizations.md.

Pattern Detail
Almost nothing is GAD-specific Of the verified organisations, only the NIMH fact sheet is dedicated to GAD; SADAG maintains a GAD section within a broader anxiety area. Everything else addresses "anxiety" — the patient-facing world reproduces the pooling problem (the diagnostic boundary)
Peer support is the core offer Anxiety UK (user-led since 1970; lived-experience advisors; therapy from £20/session), No Panic (helpline 10:00–22:00, 365 days/year, plus CBT-focused mentoring), SANE Australia (free, anonymous, professionally moderated 24/7 forums), Deutsche Angst-Hilfe (self-help group infrastructure for people, facilitators and relatives)
Geographic inversion Verified organisations cluster in the UK, Australia, Canada, US and New Zealand; single entries for South Africa, India, Germany, Denmark, Ireland and Japan. Treatment gaps are largest where organisational support is thinnest (epidemiology and burden)
Fragility Anxiety Canada's site now carries a bilingual closure notice stating the organisation ceased operations as of April 1, with a subset of resources surviving on other sites (accessed 2026-09-02)
Three major organisations unverifiable ADAA, Mind (UK) and NAMI returned HTTP 403 bot challenges on 2026-09-02, so nothing about their current content is asserted here

The numbers organisations put in front of patients

These are the figures the public actually encounters, and they differ from the research figures in instructive ways:

Source Statement Comparison with the wiki
WHO fact sheet, 8 Sep 2025 (accessed 2026-09-02) 359 million people with anxiety disorders in 2021; 4.4% of the global population; most common of all mental disorders; only 27.6% of those in need receive treatment Matches GBD 2021 (359.2 million; Zhang 2026, PMID 40935255) — anxiety disorders pooled, not GAD
Beyond Blue (accessed 2026-09-02) "Anxiety conditions affect 1 in 4 people in Australia and they are treatable" Lifetime, all anxiety disorders; compare DSM-5 GAD lifetime 3.7% (Ruscio 2017, PMID 28297020)
Mental Health America (accessed 2026-09-02) Over 21% of US adults (42.5 million) affected each year 12-month, all anxiety disorders; compare NCS-R 12-month anxiety 18.1% (Kessler 2005, PMID 15939839)
CAMH (accessed 2026-09-02) One in three adults will have an anxiety disorder in their lifetime, citing Bandelow & Michaelis 2015 Traceable to PMID 26487813 (up to 33.7% lifetime) — a rare patient-facing page that cites its source
NIMH GAD fact sheet (accessed 2026-09-02) GAD as worry "out of proportion with the situation" The excessiveness criterion, delivered to the public as settled — while its own investigators argue for removing it (Ruscio 2024, PMID 39364896)

The last row is the sharpest: the criterion that the field's own epidemiologists propose deleting is the one the public is taught to recognise the disorder by.

Advocacy priorities that the evidence supports

  1. Ask about preference, and record it. The evidence that preference matters is stronger than the evidence distinguishing the treatments (Kalpakidou 2019, PMID 31126337; Papola 2024, PMID 37851421).
  2. Fund continuity, not just protocols. CALM collaborative care produced an NNT of 5.27 for its response outcome (Roy-Byrne 2010, PMID 20483968) and includes ingredients patients name, including continuity and collaboration (Parker 2020, PMID 32059636). Its NNT should not be ranked against different drug or psychotherapy outcomes.
  3. Treat perinatal anxiety as its own target. GAD-specific prevalence is 4.1% antenatal and 5.7% postnatal (Dennis 2017, PMID 28302701). WPSI found no treatment trials through its 2020 review (Nelson 2020, PMID 32510989); a later systems-level cluster-RCT secondary analysis measured perinatal GAD symptoms among depression-screen-positive participants (Zimmermann 2024, PMID 38992743), while GAD-specific pharmacotherapy trials remain absent in a 2026-09-02 PubMed search.
  4. Support discontinuation actively. Patients describe tapering as an emotional, cognitive and relational process, not a symptom count (Mahmood 2024, PMID 39102706).
  5. Target self-reliance and mental-health literacy, not only availability. Both are named as primary barriers and their inverses as primary facilitators (Lui 2024, PMID 36084266).

Open questions

  • Why does qualitative evidence remain a tiny fraction of the GAD literature? The live audit found several GAD-specific qualitative studies, but they remain small and concentrated in treatment process, primary care and particular life stages (PMIDs: 31908140, 33218311, 35716017, 21644188, 41587136).
  • Can drug-versus-therapy comparative effectiveness be established in a population that refuses randomisation (Kalpakidou 2019, PMID 31126337)? A 2023 quasi-experimental study let GAD patients select e-CBT, medication or their combination (41, 41 and 33 participants respectively), demonstrating feasibility but leaving confounding by indication unresolved (Stephenson 2023, PMID 38125282). A randomised-preference or stronger causal comparative-effectiveness design remains a dated evidence gap.
  • What are patients' research priorities in GAD? No GAD-specific priority-setting partnership was located; the nearest is a James Lind Alliance exercise on stopping psychiatric medication generally (Boland 2025, PMID 40790920).
  • If persistence through unhelpful encounters is the binding constraint on getting helpful treatment (Stein 2021, PMID 34372811), what would increase it? Nothing in the advocacy or service literature was designed to test that.
  • Does the closure of a national organisation (Anxiety Canada) measurably change help-seeking in that country?
  • Do organisation-published prevalence figures (1 in 4, 21%, 1 in 3) help or hinder recognition of GAD specifically, given that none of them is a GAD figure?

References

  1. Hurtado MM, et al. 'I have anxiety, but I have values and preferences': Experiences of users with generalized anxiety disorder: A qualitative study. Int J Ment Health Nurs. 2020;29:521-530. PMID 31908140
  2. Kalpakidou AK, et al. Barriers to recruitment when conducting a commissioned randomised controlled trial of medication versus psychological therapy for generalised anxiety disorder: some lessons learned. Trials. 2019;20:284. PMID 31126337
  3. Parker D, et al. Patients' experiences of seeking help for emotional concerns in primary care: doctor as drug, detective and collaborator. BMC Fam Pract. 2020;21:35. PMID 32059636
  4. Fisher K, et al. Men's anxiety: A systematic review. J Affect Disord. 2021;295:688-702. PMID 34517242
  5. Lui JC, et al. Barriers and facilitators to help-seeking for common mental disorders among university students: a systematic review. J Am Coll Health. 2024;72:2605-2613. PMID 36084266
  6. Woodgate RL, et al. The experience of the self in Canadian youth living with anxiety: A qualitative study. PLoS One. 2020;15:e0228193. PMID 32004336
  7. Mahmood R, et al. The lived experience of withdrawal from Selective Serotonin Reuptake Inhibitor (SSRI) antidepressants: A qualitative interview study. Health Expect. 2024;27:e13966. PMID 39102706
  8. Boland M, et al. A Qualitative Descriptive Analysis of Free-Text Responses to a Survey on Reducing and Stopping Psychiatric Medication. Health Expect. 2025;28:e70384. PMID 40790920
  9. Oh S, et al. Exploring women's experiences of identifying, negotiating and managing perinatal anxiety: a qualitative study. BMJ Open. 2020;10:e040731. PMID 33380483
  10. Ali E. Women's experiences with postpartum anxiety disorders: a narrative literature review. Int J Womens Health. 2018;10:237-249. PMID 29881312
  11. Saeed Q, et al. Lived experiences of mothers with postnatal anxiety: a qualitative phenomenology study from Pakistan. BMJ Open. 2024;14:e078203. PMID 38772885
  12. Romera I, et al. Generalized anxiety disorder, with or without co-morbid major depressive disorder, in primary care. J Affect Disord. 2010;127:160-8. PMID 20541811
  13. Dennis CL, et al. Prevalence of antenatal and postnatal anxiety: systematic review and meta-analysis. Br J Psychiatry. 2017;210:315-323. PMID 28302701
  14. Nelson HD, et al. Screening for Anxiety in Adolescent and Adult Women. Ann Intern Med. 2020;173:29-41. PMID 32510989
  15. Roy-Byrne P, et al. Delivery of evidence-based treatment for multiple anxiety disorders in primary care: a randomized controlled trial. JAMA. 2010;303:1921-8. PMID 20483968
  16. Papola D, et al. Psychotherapies for Generalized Anxiety Disorder in Adults. JAMA Psychiatry. 2024;81:250-259. PMID 37851421
  17. Bandelow B, et al. The diagnosis of and treatment recommendations for anxiety disorders. Dtsch Arztebl Int. 2014;111:473-80. PMID 25138725
  18. Ruscio AM, et al. Cross-sectional Comparison of the Epidemiology of DSM-5 Generalized Anxiety Disorder Across the Globe. JAMA Psychiatry. 2017;74:465-475. PMID 28297020
  19. Ruscio AM, et al. The case for eliminating excessive worry as a requirement for generalized anxiety disorder. Psychol Med. 2024;54:3447-3458. PMID 39364896
  20. Kessler RC, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617-27. PMID 15939839
  21. Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015;17:327-35. PMID 26487813

  22. Zhang Z, et al. Global, regional and national burden of anxiety and depression disorders from 1990 to 2021, and forecasts up to 2040. J Affect Disord. 2026;393:120299. PMID 40935255

  23. Stein DJ, et al. Perceived helpfulness of treatment for generalized anxiety disorder: a World Mental Health Surveys report. BMC Psychiatry. 2021;21:392. PMID 34372811

  24. Zech JM, et al. Correlates of treatment-seeking in DSM-5 generalized anxiety disorder: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III. J Anxiety Disord. 2024;106:102909. PMID 39047416
  25. Hoffman DL, et al. Human and economic burden of generalized anxiety disorder. Depress Anxiety. 2008;25:72-90. PMID 17146763
  26. Stephenson C, et al. Comparing the efficacy of electronic cognitive behavioral therapy to medication and combination therapy for generalized anxiety disorder: a quasi-experimental clinical trial. Front Psychiatry. 2023;14:1194955. PMID 38125282
  27. Toledo-Chávarri A, et al. Framing the process in the implementation of care for people with generalized anxiety disorder in primary care: a qualitative evidence synthesis. BMC Fam Pract. 2020;21:237. PMID 33218311
  28. Inness BE, et al. Problematic behaviours associated with generalized anxiety disorder during pregnancy and the postpartum period: A thematic analysis. Psychol Psychother. 2022;95:921-938. PMID 35716017
  29. Marcus M, et al. Client experiences of motivational interviewing for generalized anxiety disorder: a qualitative analysis. Psychother Res. 2011;21:447-461. PMID 21644188
  30. Aucoin M, et al. Participant Experience in a Study of Dietary Counselling plus Omega-3 Supplementation for the Treatment of Generalized Anxiety Disorder among Women: A Focus Group Study. Neuropsychobiology. 2026;85:141-155. PMID 41587136
  31. Zimmermann M, et al. Comparing the effect of two systems-level interventions on perinatal generalized anxiety disorder and posttraumatic stress disorder symptoms. Am J Obstet Gynecol MFM. 2024;6:101426. PMID 38992743

Non-journal sources (all accessed 2026-09-02): World Health Organization — "Anxiety disorders" fact sheet, 8 September 2025, https://www.who.int/news-room/fact-sheets/detail/anxiety-disorders; NIMH — "Generalized Anxiety Disorder: What You Need to Know", https://www.nimh.nih.gov/health/publications/generalized-anxiety-disorder-gad; Anxiety UK — "Home", https://www.anxietyuk.org.uk/; No Panic — "Home", https://nopanic.org.uk/; SANE Australia, https://www.sane.org/; Beyond Blue — "Understand Anxiety disorders", https://www.beyondblue.org.au/mental-health/anxiety; CAMH — "Anxiety Disorders", https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/anxiety-disorders; Mental Health America — "Anxiety", https://mhanational.org/conditions/anxiety/; Deutsche Angst-Hilfe e.V., https://www.angstselbsthilfe.de/; SADAG, https://www.sadag.org/; Anxiety Canada closure notice, https://www.anxietycanada.com/.